LNTH vs NEOG vs GEHC Stock Comparison

Lantheus Holdings, Neogen and GE HealthCare Technologies Prices as of Oct 28, 2026 Peers: Industry group
LNTH Lantheus Holdings, Inc.
$100.10 +0.4% 1M +74.6% 1Y
Market cap
$6.53B
P/E
23.7x
Revenue (TTM)
$1.56B
Div. yield
–
Diagnostic Equipment Healthcare
6 wins
NEOG Neogen Corp
$12.12 -11.7% 1M +96.8% 1Y
Market cap
$2.67B
P/E
–
Revenue (TTM)
$883.99M
Div. yield
–
Diagnostic Equipment Healthcare
1 win

Head to Head

11 decided of 12

Lantheus Holdings leads on 6 of the 12 questions below (Lantheus Holdings 6, GE HealthCare Technologies 4, Neogen 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionLNTHNEOGGEHCLeader
Larger companyMarket capitalisation $6.53B $2.67B $34.75B GEHC
Cheaper on earningsLower P/E, profitable companies only 23.7x -47.5x 16.1x GEHC
Cheaper on forward earningsLower price / next fiscal year consensus EPS 17.4x 37.9x 14.9x GEHC
Faster revenue growthRevenue growth, trailing twelve months +2.3% -0.3% +6.9% GEHC
More profitableNet margin, trailing twelve months 17.7% -6.3% 10.0% LNTH
Better return on capitalReturn on invested capital 12.5% -0.2% 10.8% LNTH
Less leveragedLower net debt / EBITDA -0.1x 5.4x 2.0x LNTH
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +74.6% +96.8% -4.5% NEOG
Better 5-year returnAnnualised price return, 5 years +33.8%/yr -22.1%/yr — LNTH
Less volatileAnnualised volatility, 1 year 32.2% 55.7% 35.5% LNTH
Higher overall scoreMean of the five percentile scores vs peers 80/100 57/100 57/100 LNTH

Percentile Scorecard

LNTHNEOGGEHC

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisLNTHNEOGGEHC
Valuation 81 #44 of 227 73 #63 of 227 91 #21 of 227
Growth 62 #83 of 219 50 #111 of 219 35 #143 of 219
Profitability 94 #13 of 205 63 #76 of 205 79 #44 of 205
Financial Health 70 #73 of 237 46 #128 of 237 28 #170 of 237
Shareholder Returns 93 #11 of 135 55 #61 of 135 54 #63 of 135
Overall 80 57 57
  • LNTH ranked among 247 companies in Medical Devices and Diagnostics
  • NEOG ranked among 247 companies in Medical Devices and Diagnostics
  • GEHC ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodLNTHNEOGGEHCSPY
1 month +0.4%-11.7%+13.5% +0.9%
3 months +0.1%+28.9%+5.5% +5.9%
6 months +23.3%+34.5%+27.4% +8.5%
Year to date +50.4%+73.4%-7.6% +13.3%
1 year +74.6%+96.8%-4.5% +12.4%
3 years +49.8%-20.9%+20.2% +88.1%
3 years, per year +14.4%-7.5%+6.3% +23.5%
5 years +328.0%-71.4%— +68.2%
5 years, per year +33.8%-22.1%— +11.0%
10 years +1,128.2%-38.0%— +263.4%
10 years, per year +28.5%-4.7%— +13.8%

Risk

MeasureLNTHNEOGGEHCSPY
Volatility, 1Y 32.2%55.7%35.5% 12.7%
Downside volatility, 1Y 27.5%46.7%35.9% 12.7%
Beta vs S&P 500, 1Y 0.591.440.68 1.00
Return / volatility, 1Y 2.311.74-0.13 0.98
Max drawdown, 5Y -59.5%-90.6%-37.4% -25.4%
From 52-week high -9.8%-13.3%-14.0% -0.9%
52-week high $110.94$13.98$88.16 $779.14
52-week low $50.69$5.41$59.49 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleLNTHNEOGGEHC
P/E now vs peer median 23.7xmedian 28.8x -47.1xmedian 28.8x 15.9xmedian 28.8x
P/S now vs peer median 4.2xmedian 3.0x 3.0xmedian 3.0x 1.6xmedian 3.0x
EV/EBITDA now vs peer median 16.5xmedian 17.4x 29.3xmedian 17.4x 11.8xmedian 17.4x
P/FCF now vs peer median 16.8xmedian 25.7x 53.1xmedian 25.7x 18.1xmedian 25.7x
P/B now vs peer median 5.0xmedian 2.4x 1.3xmedian 2.4x 2.9xmedian 2.4x
PEG now vs peer median 0.22median 1.03 1.68median 1.03 1.29median 1.03

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsLNTHNEOGGEHC
Revenue $1.56B $883.99M $21.64B
Gross profit $936.02M $418.98M $8.64B
Operating income $302.34M -$7.38M $2.89B
Net income $275.31M -$56.10M $2.21B
Free cash flow $387.83M $49.80M $1.89B
R&D $173.09M $19.76M $1.31B
EPS (diluted) $4.08 $-0.26 $4.75
Cash & equivalents $593.30M $172.00M $2.86B
Total debt $571.05M $774.20M $9.97B
Shares (diluted) 67.52M 218.10M 453.00M
Enterprise value $4.70B $2.00B $22.98B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricLNTHNEOGGEHC
P/E 23.7x -47.1x 15.9x
P/FCF 16.8x 53.1x 18.1x
P/Operating cash flow 15.8x 31.0x 14.2x
P/S 4.2x 3.0x 1.6x
P/B 5.0x 1.3x 2.9x
P/Tangible book 10.5x 3.3x 3.5x
EV/EBITDA 16.5x 29.3x 11.8x
EV/EBIT 21.5x -440.3x 14.3x
EV/Revenue 4.2x 3.7x 1.9x
EV/FCF 16.8x 65.2x 21.9x
EV/Operating cash flow 15.8x 38.1x 17.1x
PEG (3Y EPS CAGR) 0.22 1.68 1.29

Growth

14 metrics
MetricLNTHNEOGGEHC
Revenue growth (1Y) 2.3% -0.3% 6.9%
Revenue CAGR (3Y) 11.4% -1.3% 3.9%
Gross profit growth (1Y) -3.4% 1.8% 4.6%
Gross profit CAGR (3Y) 16.3% -3.1% 3.9%
Operating income growth (1Y) -30.9% 99.3% 5.4%
Operating income CAGR (3Y) 118.8% -29.0% 4.6%
Net income growth (1Y) 1.6% 94.6% -3.5%
Net income CAGR (3Y) 102.1% -28.3% 7.6%
EPS growth (1Y) 5.8% 94.6% -2.0%
EPS CAGR (3Y) 105.5% -28.0% 12.3%
Operating cash flow growth (1Y) -21.7% -1.9% 30.5%
Operating cash flow CAGR (3Y) 14.5% 2.9% 4.5%
Free cash flow growth (1Y) -10.1% 1,631% 34.9%
Free cash flow CAGR (3Y) 103.0% 126.1% 2.7%

Profitability

14 metrics
MetricLNTHNEOGGEHC
Gross margin 60.1% 47.4% 39.9%
EBITDA margin 25.4% 12.5% 16.2%
Operating margin 19.4% -0.8% 13.3%
Pretax margin 23.3% -7.7% 12.8%
Net margin 17.7% -6.3% 10.0%
FCF margin 24.9% 5.6% 8.7%
Operating cash flow margin 26.5% 9.6% 11.2%
Return on equity 21.8% -2.7% 19.5%
Return on assets 11.6% -1.7% 5.8%
Return on invested capital 12.5% -0.2% 10.8%
Return on capital employed 14.8% -0.2% 10.0%
Asset turnover 0.7x 0.3x 0.6x
Cash conversion (OCF / net income) 1.5x -1.5x 1.1x
Stock comp / revenue 5.0% 1.3% 0.7%

Financial Health

11 metrics
MetricLNTHNEOGGEHC
Debt / assets 23.6% 23.4% 26.0%
Debt / equity 0.4x 0.4x 0.9x
Net debt / EBITDA -0.1x 5.4x 2.0x
Debt / FCF 1.5x 15.5x 5.3x
Liabilities / assets 45.7% 36.8% 69.7%
Equity / assets 54.3% 63.2% 30.3%
Interest coverage 15.3x – 6.6x
Current ratio 3.1x 3.9x 1.3x
Quick ratio 2.8x 2.1x 0.9x
Cash ratio 1.8x 1.2x 0.3x
Altman Z-score 5.46 1.49 1.91

Shareholder Returns

7 metrics
MetricLNTHNEOGGEHC
Dividend yield – – 0.2%
Net buyback yield 2.9% -0.1% 0.8%
Shareholder yield 2.9% -0.1% 1.0%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusLNTHNEOGGEHC
Forward P/E 17.4xFY2026 37.9xFY2026 14.9xFY2026
EPS, next fiscal year $5.76FY2026 $0.32FY2026 $5.09FY2026
EPS growth, next FY -5.3%FY2026 0.0%FY2026 +10.9%FY2026
EPS growth, the year after +4.2% +31.3% -0.4%
Revenue, next fiscal year $1.57BFY2026 $847.28MFY2026 $22.47BFY2026
Revenue growth, next FY +1.8%FY2026 -2.7%FY2026 +8.9%FY2026
Revenue growth, the year after +12.7% -1.5% +7.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersLNTHNEOGGEHC
Held by institutions 100.0% 100.0% 87.0%
Institutions holding 465 315 1,221
Change in shares held, QoQ +3.4% +1.6% +1.7%
Institutions buying 248 151 538
Institutions selling 142 106 461
Buyers to sellers 1.75 1.42 1.17

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

LNTHNEOGGEHC
LNTH 1.00 0.08 0.18
NEOG 0.08 1.00 0.27
GEHC 0.18 0.27 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, LNTH, NEOG and GEHC?

GE HealthCare Technologies (GEHC) is the largest by market capitalisation: Lantheus Holdings (LNTH) $6.53B, Neogen (NEOG) $2.67B, GE HealthCare Technologies (GEHC) $34.75B.

Which stock is cheaper, LNTH, NEOG and GEHC?

GE HealthCare Technologies (GEHC) trades on the lowest price-to-earnings ratio (Lantheus Holdings (LNTH) 23.7x, Neogen (NEOG) -47.5x, GE HealthCare Technologies (GEHC) 16.1x). On next year's consensus earnings, GE HealthCare Technologies (GEHC) is cheapest (Lantheus Holdings (LNTH) 17.4x, Neogen (NEOG) 37.9x, GE HealthCare Technologies (GEHC) 14.9x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

GE HealthCare Technologies (GEHC) grew revenue fastest over the trailing twelve months: Lantheus Holdings (LNTH) +2.3%, Neogen (NEOG) -0.3%, GE HealthCare Technologies (GEHC) +6.9%.

Which company is more profitable?

Lantheus Holdings (LNTH) has the highest net margin (Lantheus Holdings (LNTH) 17.7%, Neogen (NEOG) -6.3%, GE HealthCare Technologies (GEHC) 10.0%). On return on invested capital, Lantheus Holdings (LNTH) leads (Lantheus Holdings (LNTH) 12.5%, Neogen (NEOG) -0.2%, GE HealthCare Technologies (GEHC) 10.8%).

Which stock has performed better?

Over the past year Neogen (NEOG) returned the most: Lantheus Holdings (LNTH) +74.6%, Neogen (NEOG) +96.8%, GE HealthCare Technologies (GEHC) -4.5%. Over five years, Lantheus Holdings (LNTH) compounded fastest (Lantheus Holdings (LNTH) +33.8%/yr, Neogen (NEOG) -22.1%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Lantheus Holdings (LNTH) has been the steadiest (Lantheus Holdings (LNTH) 32.2%, Neogen (NEOG) 55.7%, GE HealthCare Technologies (GEHC) 35.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, LNTH, NEOG and GEHC?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Lantheus Holdings (LNTH) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.